Journal
BMC NEUROLOGY
Volume 16, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12883-016-0547-x
Keywords
Costs; Dementia; Drugs; Generalized linear model; Health economy; Pharmacoeconomics; Population-based study
Categories
Funding
- Ministry of Health and Social Affairs, Sweden
- Swedish Research Council
- Swedish Brain Power
- Swedish Pharmacies' Fund for Research and Studies in Health Economics and Social Pharmacy
Ask authors/readers for more resources
Background: We aimed to investigate the impact of dementia on drug costs in older people, after adjustment for socio-demographic factors, residential setting and co-morbidities. Methods: We included 4 129 individuals aged >= 60 years from The Swedish National Study on Aging and Care (SNAC) in Kungsholmen and Nordanstig 2001-2004. A generalized linear model (GLM) was used to investigate how much dementia was associated with drug costs. Results: Overall drug costs for persons with and without dementia were 6147 SEK (816 USD) and 3810 SEK (506 USD), respectively. The highest drug cost was observed for nervous system drugs among persons with dementia. The adjusted GLM showed that dementia was not associated with higher overall drug costs (beta = 1.119; ns). Comorbidities and residential setting were the most important factors for overall drug costs. Conclusion: We found that the observed higher overall drug costs for persons with dementia were due to comorbidities and residential setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available